Clinical Trials Summary for out of hours Important Reference

Lancashire Teaching Hospitals NHS Foundation Trust

Acronym study title	**Checkmate CA209848 Trial**
Study Details	**A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumours of High Tumour Mutational Burden (TMB-H)**
Principal Investigator PI **Sub PI's**	Dr Dennis Hadjiyiannakis (daytime 01772 522031) Dennis.hadjiyiannakis@lthtr.nhs.uk Dr Pedro Okoh (research medic) (01772 522031) Pedro.okoh@lthtr.nhs.uk Dr Chin (Neuro Oncologist) Chin.lim@lthtr.nhs.uk Dr Appel Wiebke.appel@lthtr.nhs.uk
Research Nurse Team	Karen Jones (Karen.jones@lthtr.nhs.uk) Alison Swan (Alison.swan@lthtr.nhs.uk) Nichola Verstraelen (Nichola.verstraelen@lthtr.nhs.uk) Daytime contact (01772 522031) Alternative daytime contact Stephanie Cornthwaite (Stephanie.cornthwaite@lthtr.nhs.uk) (01772 523581)
Drug therapy	Randomised to either: Nivolumab monotherapy or Combination of Nivolumab & Ipilimumab
In the event that a patient calls this hotline for advise	Please treat as per clinical protocols and inform the clinical and research teams. If you need further specific advice there is a 24 hour line to Bristol Myers Squibb: 01895 523000 where they can give further guidance.
Further info	This combination of medications are licensed for use in melanoma currently please refer to these clinical protocols if needed: https://www.healthierlsc.co.uk/application/files/3515/4221/3005/Melanoma_Nivolumab_ipi_v4.pdf